A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type 2 diabetes and obesity, in patients with neuroendocrine neoplasms (NENs). While semaglutide has proven effective in managing blood sugar and promoting weight loss, its effects on certain rare cancer types … Continue reading Research Reveals Potential Risks of Popular GLP-1 Medications for Some with Neuroendocrine Cancer